Futibatinib, sold under the brand name Lytgobi, is an anti-cancer medication used for the treatment of

cholangiocarcinoma Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever. Light colored stool ...

(bile duct cancer). It is a kinase inhibitor. It is taken by mouth. Futibatinib was approved for medical use in the United States in September 2022.

Medical uses

Futibatinib is

indicated In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication. An indication can commonly be confused with the term diagnosis. A diagnosis ...

for the treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

Names

Futibatinib is the international nonproprietary name (INN).

References

Antineoplastic drugs Pyrazolopyrimidines Methoxy compounds Amines {{Pharma-stub